Pentoxifylline for diabetic kidney disease.

Area of Science:

• Nephrology
• Pharmacology
• Diabetology

Background:

• Diabetic kidney disease (DKD) significantly increases morbidity and mortality, often due to cardiovascular complications.
• Inflammation plays a key role in DKD pathogenesis, with elevated inflammatory markers observed in affected individuals.
• Pentoxifylline, a phosphodiesterase inhibitor, exhibits anti-inflammatory and immunoregulatory properties, suggesting potential therapeutic benefits for DKD.

Purpose of the Study:

• To systematically evaluate the efficacy and safety of pentoxifylline in treating patients diagnosed with diabetic kidney disease (DKD).
• To assess the impact of pentoxifylline on renal function markers, proteinuria, and blood pressure in DKD patients.

Main Methods:

• Conducted a comprehensive literature search across multiple databases, including Cochrane Renal Group's specialized register, CENTRAL, MEDLINE, EMBASE, and Chinese biomedical databases.
• Included all randomized controlled trials (RCTs) and quasi-RCTs investigating pentoxifylline for DKD.
• Performed meta-analyses using random effects models to pool data on dichotomous and continuous outcomes, assessing risk ratios, mean differences, and standardized mean differences.

Main Results:

• In 17 studies with 991 participants, pentoxifylline significantly reduced serum creatinine and albuminuria compared to placebo.
• Pentoxifylline also significantly reduced albuminuria and proteinuria when compared to routine treatment alone.
• No significant differences in renal function or blood pressure were observed when compared to active comparators like captopril or clonidine/methyldopa; adverse events were mild.

Conclusions:

• Pentoxifylline demonstrates potential benefits in improving renal function and reducing proteinuria in DKD patients with a favorable safety profile.
• However, the current evidence is limited by the poor methodological quality, small sample sizes, and high risk of bias in the included studies.
• Further rigorously designed, large-scale, multicenter randomized controlled trials are essential to confirm the therapeutic efficacy of pentoxifylline for DKD.